The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Effects of delayed sodium thiosulfate on cisplatin-induced ototoxicity in pediatric and adolescent patients with cancer: Results from the Japanese Children’s Cancer Group STS-J01 study.
 
Eiso Hiyama
Research Funding - Fennec Pharma
 
Isamu Saeki
No Relationships to Disclose
 
Eriko Uchida
No Relationships to Disclose
 
Makiko Mori
No Relationships to Disclose
 
Yuki Yuza
No Relationships to Disclose
 
Masakatsu Yanagimachi
No Relationships to Disclose
 
Kenichiro Watanabe
No Relationships to Disclose
 
Tomoko Iehara
No Relationships to Disclose
 
Hiroyuki Fujisaki
No Relationships to Disclose
 
Daiichiro Hasegawa
No Relationships to Disclose
 
Utako Oba
No Relationships to Disclose
 
Chikako Kiyotani
No Relationships to Disclose
 
Miho Kato
No Relationships to Disclose
 
Kenichi Yoshimura
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Eisai; Lilly; Nihon-Shinyaku; Nihonkayaku; Novartis; Otsuka; Pfizer; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - BrightPath Biotheraputics; Nippon Shinyaku; Sysmex
 
Kimura Toshimi
No Relationships to Disclose
 
Taizo Hirata
No Relationships to Disclose
 
Pierre Sayad
Employment - Fennec Pharmaceuticals
Leadership - Fennec Pharmaceuticals
Stock and Other Ownership Interests - Fennec Pharmaceuticals